Al-Riyami and Paterson’s Protocol Sample Clauses

Al-Riyami and Paterson’s Protocol. ‌ Al-Riyami and Paterson [1] introduced in their paper on certificateless public key cryp- tography a simple certificateless authenticated two-party key agreement protocol. The initialization of the protocol is formally specified using the algorithms of certificateless public key cryptography [1]. These include Setup, Partial-Private-Key-Extract, Set-Secret-Value, Set-Private-Key, and Set-Public Key. These algorithms are ex- plained in detail in Appendix A.1. Assume that entities A and B wish to agree on a secret key. They first each choose the random ephemeral values a, b ∈ Zq∗ as usual, and create the corresponding ephemeral public keys aP, bP ∈ G1 respectively. A then sends the ephemeral key TA = aP and A’s public key PA = ⟨XA, YA⟩ to B, who then in the same fashion responds with TB = bP and PB = ⟨XB, YB⟩ to A. Here, Xi = xiP and Yi = xiP0 = xisP, where xi is an entity’s long-term secret value and s is the KGC master key. A B a ∈ Z∗q TA, ⟨XA, YA⟩ b ∈ Z∗q → ê(XB, P0)? = ê(YB , P) −−−−−−−−−−−−− TB, ⟨XB, YB⟩ ê(XA, P0)? = ê(YA , P) KA = ê(QB , YB )a · ê(SA, TB) ←−−−−−−−−−−−−− KB = ê(QA , YA )b · ê(SB, TA) K = KA = KB = ê(SB, TA) · ê(SA, TB) FK = H(K abP) Figure 7: Al-Riyami and Paterson’s Protocol Once the messages are exchanged, both users verify that the same KGC master key has been used in each other’s public keys. A checks if ê(XB, P0) = ê(YB, P) and B checks if ê(XA, P0) = ê(YA, P). See that ê(xiP, sP) = ê(xisP, P) = ê(xiP, P)s. A then computes KA = ê(QB, YB)a · ê(SA, TB) and B computes KB = ê(QA, YA)b · ê(SB, TA), such that K = KA = KB becomes the shared key between A and B. Both entities then compute the → session key FK = H1(K abP) where H1 : G2 × G1 {0, 1}k. As pointed out by the authors, the protocol is vulnerable to a man-in-the-middle attack if the KGC replaces both the short-term and long-term public keys exchanged in a proto- col run. The reason only a KGC can mount such an attack is because the corresponding (partial) private key must be obtained in order to compute K. However, such an attack can be mounted on all certificateless schemes, and therefore it must be assumed that the KGC is trusted not to replace public keys. Note that the protocol may be weak against denial-of-service attacks as an adversary with no attachment to the KGC, may efficiently compute valid public keys simply by knowing (P, P0) and repeatedly query the victim to compute keys. For each key received, the victim will need to compute four pairings, and thus the computatio...
Sample 1
AutoNDA by SimpleDocs

Related to Al-Riyami and Paterson’s Protocol

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Musculoskeletal Injury Prevention and Control (a) The Hospital in consultation with the Joint Health and Safety Committee (JHSC) shall develop, establish and put into effect, musculoskeletal prevention and control measures, procedures, practices and training for the health and safety of employees.

  • Placement of DNS probes Probes for measuring DNS parameters shall be placed as near as possible to the DNS resolvers on the networks with the most users across the different geographic regions; care shall be taken not to deploy probes behind high propagation-­‐delay links, such as satellite links.

  • Country and Territory Names The country and territory names (including their IDN variants, where applicable) contained in the following internationally recognized lists shall be withheld from registration or allocated to Registry Operator at All Levels:

  • Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.

  • Gold Open Access Articles May be shared according to the author-selected end-user license and should contain a CrossMark logo, the end user license, and a DOI link to the formal publication on ScienceDirect. Please refer to Elsevier's posting policy for further information.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Intercept and Referral Announcements 6.1 When a Customer changes its service provider from Verizon to CBB, or from CBB to Verizon, and does not retain its original telephone number, the Party formerly providing service to such Customer shall provide a referral announcement (“Referral Announcement”) on the abandoned telephone number which provides the Customer’s new number or other appropriate information, to the extent known to the Party formerly providing service. Notwithstanding the foregoing, a Party shall not be obligated under this Section to provide a Referral Announcement if the Customer owes the Party unpaid overdue amounts or the Customer requests that no Referral Announcement be provided.

Time is Money Join Law Insider Premium to draft better contracts faster.